GTBP · GT Biopharma, Inc. · Analyst Estimates
$3.72
-0.12 (-3.13%)
At close · Nov 13
Return incl. dividend (before tax)
Q2 2021 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.71M
Shares
1.80M
Volume · Nov 13
66.92K
Avg daily vol (48 sessions)
89.87K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for GT Biopharma, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-14 05:22 UTC · Publication dates shown per estimate · 2 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
Key facts
CIK
109657
CUSIP
36254L407
13F (30d)
26 filings
18 filers
Visit website
Investor relations